Complete Freund’s adjuvant (CFA) is used in laboratory animals to stimulate strong immune responses. However, it can cause persistent local inflammation and tissue damage, raising welfare concerns. This scoping review aimed to (i) assess how frequently welfare-relevant outcomes are reported in CFA immunisation and antibody-production studies in mice, rats and rabbits; (ii) describe reported welfare-relevant outcomes and the methods used to assess them; (iii) chart CFA regimen details across studies; and (iv) summarise reported alternatives to CFA, including welfare comparisons where available. We followed a protocol registered in Systematic Reviews for Animals and Food and reported in accordance with PRISMA-ScR. We searched PubMed and Embase from 2015 onwards. Screening was conducted in two phases (title/abstract; full text) by one reviewer, with uncertainties resolved by a second reviewer. Data were charted on animal characteristics, CFA regimen details, welfare monitoring, reported local/systemic outcomes, analgesia/humane endpoints and comparator adjuvants. Of 1608 records screened, 689 were assessed at full-text level and 43 met inclusion criteria by reporting a welfare-relevant outcome (including ‘no adverse effects’): local outcomes were reported in 24/43 and systemic in 8/43; structured pain or behaviour monitoring occurred in 4/43 and formal scoring in 1/43 studies. Alternatives were evaluated in 32/43; in studies involving head-to-head comparisons with CFA (28/32), alternatives were more often better tolerated (22/28) than similar (6/28), with efficacy usually comparable or higher (31/32). Despite well-recognised welfare concerns with CFA, welfare-relevant outcomes are rarely reported. Standardised reporting of CFA regimens, welfare assessment methods and results is needed to support evidence-based refinement and comparison with alternatives.
StillsHF.Adjuvants and antibody production: Dispelling the myths associated with Freund’s complete and other adjuvants. ILAR J2005; 46: 280–293.
2.
CoxJCCoulterAR.Adjuvants – a classification and review of their modes of action. Vaccine1997; 15: 248–256.
3.
ViegasBJFHalderMEWhelanM. EURL ECVAM recommendation on non-animal-derived antibodies. Luxembourg: Publications Office of the European Union. https://doi.org/10.2760/80554.
4.
LazarevićMStanisavljevićSNikolovskiN, et al. Complete Freund’s adjuvant as a confounding factor in multiple sclerosis research. Front Immunol2024; 15: 1353865. https://doi.org/10.3389/fimmu.2024.1353865
5.
LeenaarsPPAMKoedamMAWesterPW, et al. Assessment of side effects induced by injection of different adjuvant/antigen combinations in rabbits and mice. Lab Anim1998; 32: 387–406.
6.
ApostólicoJDSLunardelliVASCoiradaFC, et al. Adjuvants: Classification, modus operandi, and licensing. J Immunol Res2016; 2016: 1459394. https://doi.org/10.1155/2016/1459394
7.
StillsHBaileyMQ.The use of Freund’s complete adjuvant. Lab Anim1991; 20: 25–30.
8.
BastolaRNohGKeumT, et al. Vaccine adjuvants: Smart components to boost the immune system. Arch Pharm Res2017; 40: 1238–1248.
9.
BilliauAMatthysP.Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J Leukoc Biol2001; 70: 849–860.
FishbackJEStronskySMGreenCA, et al. Antibody production in rabbits administered Freund’s complete adjuvant and carprofen concurrently. Lab Anim (NY)2016; 45: 63–66.
17.
TsibezovVVBashmakovYKPristenskiyDV, et al. Generation and application of monoclonal antibody against lycopene. Monoclon Antib Immunodiagn Immunother2017; 36: 62–67.
18.
KubotaMIizasaEChuumaY, et al. Adjuvant activity of Mycobacteria-derived mycolic acids. Heliyon2020; 6: e04064. https://doi.org/10.1136/bmj.g7647
19.
JinSZhangJNaharUJ, et al. Activity relationship of poly(ethylenimine)-based liposomes as Group A streptococcus vaccine delivery systems. ACS Infect Dis2023; 9: 1570–1581.
20.
LeeESWalkerCSCMoskowitzJE, et al. Cationic liposome–oligonucleotide complex as an alternative adjuvant for polyclonal antibody production in New Zealand White rabbits (Oryctolagus cuniculus). Comp Med2017; 67: 498.
21.
HuGHongCMiaoY, et al. Zeolitic imidazole framework-8 nanoparticles as an alternative to Freund’s adjuvant for Klebsiella pneumoniae recombinant protein vaccine. Biotechnol Bioeng2025; 122: 1284–1295.
22.
D’SouzaAAYevateSVBandivdekarAH, et al. In situ polyethylene sebacate particulate carriers as an alternative to Freund’s adjuvant for delivery of a contraceptive peptide vaccine – a feasibility study. Int J Pharm2015; 496: 601–608.
23.
Droppa-AlmeidaDVivasWLPSilvaKKO, et al. Recombinant CP40 from Corynebacterium pseudotuberculosis confers protection in mice after challenge with a virulent strain. Vaccine2016; 34: 1091–1096.
24.
NaharUJWangJShalashAO, et al. Self-assembled monovalent lipidated mannose ligand as a standalone nanoadjuvant. Vaccine2024; 42: 126060. https://doi.org/10.1016/j.vaccine.2024.06.027
25.
WangQSunXHuangX, et al. Nanoparticles of chitosan/poly(D,L-lactide-co-glycolide) enhanced the immune responses of Haemonchus contortus HCA59 antigen in model mice. Int J Nanomedicine2021; 16: 3125–3139.
26.
DakterzadaFMohabati MobarezAHabibi RoudkenarM, et al. Induction of humoral immune response against Pseudomonas aeruginosa flagellin(1-161) using gold nanoparticles as an adjuvant. Vaccine2016; 34: 1472–1479.
27.
KlimkaAMichelsLGlowallaE, et al. Montanide ISA 71 VG is advantageous to Freund’s adjuvant in immunization against S. aureus infection of mice. Scand J Immunol2015; 81: 291–297.
28.
AlshboolFZKarimZAPaez EspinosaEV, et al. Investigation of a thromboxane A2 receptor-based vaccine for managing thrombogenesis. J Am Heart Assoc2018; 7: e009139. https://doi.org/10.1161/JAHA.118.009139
29.
VigneswaranYHanHDe LoeraR, et al. This paper is the winner of an SFB Award in the Hospital Intern, Residency category: Peptide biomaterials raising adaptive immune responses in wound healing contexts. J Biomed Mater Res A2016; 104: 1853–1862.
30.
JinJWTangSQRongMZ, et al. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses. Acta Biomater2018; 78: 211–223.
31.
Van AalstSLudwigISVan Der ZeeR, et al. Bystander activation of irrelevant CD4+ T cells following antigen-specific vaccination occurs in the presence and absence of adjuvant. PLoS One2017; 12: e0177365. https://doi.org/10.1371/journal.pone.0177365
32.
IsaHIFerreiraGCHCraffordJE, et al. Raising antibodies against epoxyscillirosidine, the toxic principle contained in Moraea pallida Bak. (Iridaceae), in rabbits. J Immunol Methods2019; 474: 112670. https://doi.org/10.1016/j.jim.2019.112670
33.
StelznerJJBehrensMBehrensSE, et al. Squalene containing solid lipid nanoparticles, a promising adjuvant system for yeast vaccines. Vaccine2018; 36: 2314–2320.
34.
JavadiMMSoleimaniNZandiA.Enhancing breast cancer immunotherapy using gold nanoparticles carrying tumor antigens. Sci Rep2025; 15: 16747. https://doi.org/10.1038/s41598-025-97343-2
35.
CaoYBansalGPMerinoK, et al. Immunological cross-reactivity between malaria vaccine target antigen P48/45 in plasmodium vivax and P. falciparum and cross-boosting of immune responses. PLoS One2016; 11: e0158212. https://doi.org/10.1371/journal.pone.0158212
36.
HwangSHShinMSYoonTJ, et al. Immunoadjuvant activity in mice of polysaccharides isolated from the leaves of Panax ginseng C.A. Meyer. Int J Biol Macromol2018; 107: 2695–2700.
37.
DuongVTKoiralaPChenSPR, et al. Multiepitope subunit peptide-based nanovaccine against Porcine Circovirus Type 2 (PCV2) elicited high antibody titers in vaccinated mice. Molecules2023; 28: 2248. https://doi.org/10.3390/molecules28052248
38.
KampylafkaEIAlexopoulosHEl HamidiehA, et al. Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4. Autoimmunity2015; 48: 453–459.
39.
LiuFShangKJiaD, et al. Evaluation of the C protein of BVDV as a vaccine candidate: Immunoprotective studies in mice. Vet Microbiol2025; 310: 110719. https://doi.org/10.1016/j.vetmic.2025.110719
40.
BaudouFGHerreraMVargasM, et al. Immunization of rabbits with nanovenom composed of Dendroaspis polylepis venom and silica nanoparticles: A first in vivo approach. Toxicon2025; 264: 108462. https://doi.org/10.1016/j.toxicon.2025.108462
41.
FuscoLSLopezGLMaslovskiF, et al. Evaluation of a nanostructured CpG-ODN/ascorbyl palmitate as a safe and effective adjuvant for anticrotalic PLA2 serum. Trans R Soc Trop Med Hyg2025; 119: 1070–1083.
42.
LiMSuiJWangX, et al. Single-walled carbon nanotube-protein complex: A strategy to improve the immune response to protein in mice. Vaccine2024; 42: 126013. https://doi.org/10.1016/j.vaccine.2024.05.061
43.
ShalashAOWangWXiaY, et al. Evaluation of novel single-dose vaccine candidates against gonadotropin-releasing hormone (GnRH) in mice. Vaccine2025; 53: 127092. https://doi.org/10.1016/j.vaccine.2025.127092
44.
NebangwaDNEfetiMTMomnouguiSME, et al. Safety and immunogenicity of an adjuvanted human onchocerciasis vaccine candidate, OvMANE1: Preclinical evaluation in a mice model. Clin Transl Immunol 2026; 15: e70114. https://doi.org/10.1002/cti2.70114
45.
XuZZhangYWangY, et al. Evaluation of the safety and immune protection of OMPAC, PAPF, and EBPSs recombinant subunit vaccines Developed for Escherichia coli, Staphylococcus aureus, and Streptococcus agalactiae in mice. Int Immunopharmacol2025; 148: 114151. https://doi.org/10.1016/j.intimp.2025.114151
46.
BaleviAToslakEEUsluA, et al. Immunogenicity and protective efficacy of seven candidate vaccines boosted with recombinant proteins, whole-cell bacterins of three serotypes of Mannheimia haemolytica, and an emulsion-type adjuvant. Front Vet Sci2025; 12: 1553396. https://doi.org/10.3389/fvets.2025.1553396
47.
DongBHuWZhangS, et al. Immunogenicity of a recombinant subunit vaccine against feline coronavirus: A comparative study of three different adjuvants. Iran J Immunol2025; 22: 207–215.
48.
XuPTangSJiangL, et al. Nanomaterial-dependent immunoregulation of dendritic cells and its effects on biological activities of contraceptive nanovaccines. J Control Release2016; 225: 252–268.
49.
EvtushenkoERyabchevskayaEKovalenkoA, et al. Wuhan sequence-based recombinant antigens expressed in E. coli elicit antibodies capable of binding with omicron S-protein. Int J Mol Sci2024; 25: 9016. https://doi.org/10.3390/ijms25169016
50.
LopezGLVan de VeldeAHernándezD, et al. Potential low-impact immunogen for the production of anti-bothropic serum: Bothrops alternatus venom treated with Na2EDTA. Toxicon2024; 237: 107351. https://doi.org/10.1016/j.toxicon.2023.107351
51.
LinHHWangCYHsiehFJ, et al. Nanodiamonds-in-oil emulsions elicit potent immune responses for effective vaccination and therapeutics. Nanomedicine2023; 18: 1045–1059.
52.
AzuarALiZShibuMA, et al. Poly(hydrophobic amino acid)-based self-adjuvanting nanoparticles for Group A Streptococcus vaccine delivery. J Med Chem2021; 64: 2648–2658.
53.
MohammadzadehSRoohvandFEhsaniP, et al. Canola oilseed- and Escherichia coli-derived hepatitis C virus (HCV) core proteins adjuvanted with oil bodies, induced robust Th1-oriented immune responses in immunized mice. APMIS2020; 128: 593–602.
54.
WangNZhangSWangD, et al. Protective humoral immunity in guinea pigs induced by PCV2 virus-like particles displaying the B cell linear epitope (228QQITDA233) of PPV1. Vet Microbiol2019; 235: 86–92.
55.
LiuRLiuYLanM, et al. Evaluation of a water-soluble adjuvant for the development of monoclonal antibodies against small-molecule compounds. J Zhejiang Univ Sci B2016; 17: 282–293.
56.
ZhangNChannappanavarRMaC, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol2016; 13: 180–190.
57.
De Souza ApostólicoJBoscardinSBYamamotoMM, et al. HIV envelope trimer specific immune response is influenced by different adjuvant formulations and heterologous prime-boost. PLoS One2016; 11: e0145637. https://doi.org/10.1371/journal.pone.0145637
58.
BontempiIAViccoMHCabreraG, et al. Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease. Vaccine2015; 33: 1274–1283.
59.
du SertNPHurstVAhluwaliaA, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol2020; 18: e3000410. https://doi.org/10.1371/journal.pbio.3000410
60.
EggelMWürbelH.Internal consistency and compatibility of the 3Rs and 3Vs principles for project evaluation of animal research. Lab Anim2021; 55: 233–243.
61.
CarboneL.Pain in laboratory animals: The ethical and regulatory imperatives. PLoS One2011; 6: e21578.
62.
BrucknerTWieschowskiSHeiderM, et al. Measurement challenges and causes of incomplete results reporting of biomedical animal studies: Results from an interview study. PLoS One2022; 17: e0271976.
63.
LangfordDJBaileyALChandaML, et al. Coding of facial expressions of pain in the laboratory mouse. Nat Methods2010; 7: 447–449.
64.
KeatingSCJThomasAAFlecknellPA, et al. Evaluation of EMLA cream for preventing pain during tattooing of rabbits: Changes in physiological, behavioural and facial expression responses. PLoS One2012; 7: e44437.
65.
ThallmairMDuque-CorreaMJHeimannM, et al. One size does not fit all: Guidelines for designing a score sheet for animal experiments – eight essential steps. Lab Anim2026; 60: 110–118. https://doi.org/10.1177/00236772251374409
66.
CarboneLAustinJ.Pain and laboratory animals: Publication practices for better data reproducibility and better animal welfare. PLoS One2016; 11: e0155001.
67.
SmithAJCluttonRELilleyE, et al. PREPARE: Guidelines for planning animal research and testing. Lab Anim2018; 52: 135–141.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
